Literature DB >> 31877302

Ubiquitin-like protein FAT10 promotes osteosarcoma growth by modifying the ubiquitination and degradation of YAP1.

Xuan Yi1, Xueqiang Deng1, Yanzhi Zhao2, Binbin Deng1, Jianyong Deng1, Huimin Fan3, Yunyan Du4, Liang Hao5.   

Abstract

Osteosarcoma is a common malignancy of the bone tissue. The rapid growth exhibited by this cancer is a primary challenge in its treatment. In many types of cancers, FAT10, a ubiquitin-like protein, is involved in several biological activities, especially cell proliferation. Herein, we demonstrate that FAT10 plays a vital role in tumorigenesis and is overexpressed in tumor tissues compared to its expression in adjacent normal tissues. Functional assays revealed that knockdown of FAT10 expression significantly repressed the proliferation of osteosarcoma in vitro and in vivo. Furthermore, our results indicate that FAT10 exhibits oncogenic functions by regulating the level of YAP1, a key protein of the Hippo/YAP signaling pathway, and a significant positive correlation exists between the levels of FAT10 and YAP1. Further analysis showed that FAT10-induced growth of osteosarcoma cells is dependent on YAP1. Mechanistically, FAT10 stabilizes YAP1 expression by regulating its ubiquitination and degradation. Taken together, our results link the two drivers of cell growth in osteosarcoma and reveal a novel pathway for FAT10 regulation. We provide new evidence for the biological and clinical significance of FAT10 as a potential biomarker for osteosarcoma.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FAT10; Osteosarcoma; Proliferation; Ubiquitination; YAP1

Mesh:

Substances:

Year:  2019        PMID: 31877302     DOI: 10.1016/j.yexcr.2019.111804

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  TRPS1 and YAP1 Regulate Cell Proliferation and Drug Resistance of Osteosarcoma via Competitively Binding to the Target of circTADA2A - miR-129-5p.

Authors:  Jinyu Zhang; Xiang Ma; Ruiqi Zhou; Yichi Zhou
Journal:  Onco Targets Ther       Date:  2020-12-01       Impact factor: 4.147

Review 2.  Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Mahshad Kalantari; Reza Mohammadinejad; Tahereh Javaheri; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2020-06-03       Impact factor: 5.923

Review 3.  Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?

Authors:  Sarah Morice; Geoffroy Danieau; Françoise Rédini; Bénédicte Brounais-Le-Royer; Franck Verrecchia
Journal:  Cancers (Basel)       Date:  2020-03-10       Impact factor: 6.639

4.  miR-140 inhibits osteosarcoma progression by impairing USP22-mediated LSD1 stabilization and promoting p21 expression.

Authors:  Wei Liu; Dunwei Wang; Lidi Liu; Lin Wang; Ming Yan
Journal:  Mol Ther Nucleic Acids       Date:  2021-02-03       Impact factor: 8.886

Review 5.  Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling.

Authors:  Anmol Sharma; Heena Khan; Thakur Gurjeet Singh; Amarjot Kaur Grewal; Agnieszka Najda; Małgorzata Kawecka-Radomska; Mohamed Kamel; Ahmed E Altyar; Mohamed M Abdel-Daim
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

6.  Loss of SPTBN1 Suppresses Autophagy Via SETD7-mediated YAP Methylation in Hepatocellular Carcinoma Initiation and Development.

Authors:  Shuyi Chen; Huijie Wu; Zhengyang Wang; Mengping Jia; Jieyu Guo; Jiayu Jin; Xiaobo Li; Dan Meng; Ling Lin; Aiwu Ruth He; Ping Zhou; Xiuling Zhi
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2021-11-02

7.  Ubiquitin-Like Protein UBD Promotes Cell Proliferation in Colorectal Cancer by Facilitating p53 Degradation.

Authors:  Hongbin Su; Mengdi Qin; Qiang Liu; Bo Jin; Xianjun Shi; Zheng Xiang
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

8.  E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1.

Authors:  Xueqiang Deng; Xiaowei Fu; Hong Teng; Lu Fang; Bo Liang; Rengui Zeng; Lian Chen; Yeqing Zou
Journal:  J Transl Med       Date:  2021-08-05       Impact factor: 5.531

9.  Low GNG12 Expression Predicts Adverse Outcomes: A Potential Therapeutic Target for Osteosarcoma.

Authors:  Jinghong Yuan; Zhao Yuan; Aifang Ye; Tianlong Wu; Jingyu Jia; Jia Guo; Jian Zhang; Tao Li; Xigao Cheng
Journal:  Front Immunol       Date:  2021-10-06       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.